Cargando…

The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis

Cancer-related anorexia/cachexia syndrome (CACS) is characterized by anorexia and loss of body weight. Evidence is insufficient to strongly endorse any pharmacologic agent for the treatment of CACS. In this systematic review, we assessed the efficacy of oral anamorelin treatment for patients with CA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taniguchi, Jumpei, Mikura, Sunao, da Silva Lopes, Katharina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502008/ https://www.ncbi.nlm.nih.gov/pubmed/37709824 http://dx.doi.org/10.1038/s41598-023-42446-x

Ejemplares similares

Evidence for partial pharmaceutical reversal of the cancer anorexia–cachexia syndrome: the case of anamorelin
por: Anker, Stefan D, et al.
Publicado: (2015)

Anamorelin hydrochloride in the treatment of cancer anorexia–cachexia syndrome: design, development, and potential place in therapy
por: Graf, Solomon A, et al.
Publicado: (2017)

Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile
por: Pietra, Claudio, et al.
Publicado: (2014)

Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study
por: Takayama, Koichi, et al.
Publicado: (2022)

Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia
por: Tsukiyama, Ikuto, et al.
Publicado: (2023)

Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia
por: Takeda, Tsuyoshi, et al.
Publicado: (2022)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Leptin in Anorexia and Cachexia Syndrome
por: Engineer, Diana R., et al.
Publicado: (2012)

Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model
por: Hanada, Kako, et al.
Publicado: (2022)

Oncology Update: Anamorelin
por: Prommer, Eric
Publicado: (2017)

Pathophysiology of anorexia in the cancer cachexia syndrome
por: Ezeoke, Chukwuemeka Charles, et al.
Publicado: (2015)

Megestrol acetate for cachexia–anorexia syndrome. A systematic review
por: Ruiz‐García, Vicente, et al.
Publicado: (2018)

Optimal management of cancer anorexia–cachexia syndrome
por: Argilés, Josep M, et al.
Publicado: (2010)

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia
por: Currow, D., et al.
Publicado: (2017)

Megestrol acetate in cachexia and anorexia
por: Yeh, Shing-shing, et al.
Publicado: (2006)

Cachexia-anorexia in cancer patients
Publicado: (1996)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in advanced gastrointestinal cancer patients with cancer cachexia
por: Hamauchi, Satoshi, et al.
Publicado: (2019)

A case of squamous cell lung cancer treated with anamorelin in combination with a multidisciplinary collaborative approach for treating cancer cachexia
por: Oshima, Yuri, et al.
Publicado: (2022)

Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia
por: Peixoto da Silva, Sara, et al.
Publicado: (2020)

Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome
por: Mantovani, Giovanni, et al.
Publicado: (2013)

Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion
por: Currow, David C., et al.
Publicado: (2018)

Safety of Megestrol Acetate in Palliating Anorexia-Cachexia Syndrome in Patients with Castration-Resistant Prostate Cancer
por: Hong, Sungwoo, et al.
Publicado: (2013)

Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome
por: Fujitsuka, Naoki, et al.
Publicado: (2014)

Cachexia Anorexia Syndrome and Associated Metabolic Dysfunction in Peritoneal Metastasis
por: Archid, Rami, et al.
Publicado: (2019)

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial
por: Takayama, Koichi, et al.
Publicado: (2016)

A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index
por: Naito, Tateaki, et al.
Publicado: (2022)

A Systematic Review and Meta-Analysis of the Clinical Use of Megestrol Acetate for Cancer-Related Anorexia/Cachexia
por: Lim, Yu Liang, et al.
Publicado: (2022)

Refractory Monomorphic Ventricular Tachycardia Induced by Anamorelin
por: Sakagami, Hiroaki, et al.
Publicado: (2022)

Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome [Retraction]
Publicado: (2013)

Supplementary Oral Anamorelin Mitigates Anorexia and Skeletal Muscle Atrophy Induced by Gemcitabine Plus Cisplatin Systemic Chemotherapy in a Mouse Model
por: Miyake, Makito, et al.
Publicado: (2020)

The regulatory approval of anamorelin for treatment of cachexia in patients with non‐small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: facts and numbers.
por: Wakabayashi, Hidetaka, et al.
Publicado: (2020)

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
por: Garcia, Jose M, et al.
Publicado: (2014)

Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC
por: Blauwhoff-Buskermolen, Susanne, et al.
Publicado: (2017)

Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia
por: Yeom, Eunbyul, et al.
Publicado: (2022)

Appetite and food intake results from phase I studies of anamorelin
por: Blum, Robert A., et al.
Publicado: (2019)

An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin
por: Leese, Philip T, et al.
Publicado: (2015)

Anorexia–cachexia syndrome-like hypothalamic neuroendocrine dysfunction in a patient with a papillary craniopharyngioma
por: Balcázar-Hernández, Lourdes, et al.
Publicado: (2017)

Efficacy and safety of pediatric massage in the treatment of anorexia: A protocol for systematic review and meta-analysis
por: Yi, Baoxiu, et al.
Publicado: (2021)

Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival
por: Fujitsuka, N, et al.
Publicado: (2011)

Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia
por: Morley, John E.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_33an6kv6hs8s0vgs55rabhmo7u